Skip to main content
Log in

Fortgeschrittenes Zervixkarzinom

Überlebensverbesserung durch Bevacizumab

Advanced cervical cancer

Improved survival with bevacizumab

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus Irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2345

    Article  CAS  PubMed  Google Scholar 

  2. Kitagawa R, Katsumata N, Shibata T et al (2012) A randomized phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IV b persistent or recurrent cervical cancer: Japan Clinical Oncology Group Study (JCOG0505). J Clin Oncol 30(Suppl), Abstract 5006

  3. Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus Bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Klaiber-Hakimi gibt an, dass kein Interessenkonflikt besteht. Der Beitrag enthält keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Klaiber-Hakimi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klaiber-Hakimi, M. Fortgeschrittenes Zervixkarzinom. Onkologe 21, 67–68 (2015). https://doi.org/10.1007/s00761-014-2842-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-014-2842-8

Navigation